How Feasible is the Use of Saliva for Antiviral Therapeutic Drug Monitoring? A Systematic Review and Analysis.

IF 4 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Clinical Pharmacokinetics Pub Date : 2026-08-01 Epub Date: 2026-08-05 DOI:10.1007/s40262-026-01675-9
Cassandra Weng-Yan Lai, Suzanne A M Wenker, Paul W Groundwater, Justin Beardsley, Gaurav Sutrave, Ricky Hao Chen, Anne-Grete Märtson, Jan-Willem C Alffenaar
{"title":"How Feasible is the Use of Saliva for Antiviral Therapeutic Drug Monitoring? A Systematic Review and Analysis.","authors":"Cassandra Weng-Yan Lai, Suzanne A M Wenker, Paul W Groundwater, Justin Beardsley, Gaurav Sutrave, Ricky Hao Chen, Anne-Grete Märtson, Jan-Willem C Alffenaar","doi":"10.1007/s40262-026-01675-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Immunosuppressed patients are susceptible to serious viral infections, often necessitating antiviral prophylaxis and/or treatment. Therapeutic drug monitoring (TDM) has been proposed to optimise drug exposure and clinical outcomes and is typically performed on full blood/plasma samples. Saliva offers a less invasive, patient-friendly approach, and this systematic review aims to assess the feasibility of saliva-based assays for antiviral TDM.</p><p><strong>Methods: </strong>We conducted a search on MEDLINE, EMBASE and ClinicalTrials.gov databases, governmental regulatory websites and conference abstracts. Primary studies reporting both saliva and plasma concentrations of antivirals used forprophylaxis or treatment of opportunistic viral infections were included. Physicochemical properties of eachantiviral were compiled from PubChem and DrugBank to predict salivary excretion. Feasibility classifications were defined as follows: (1) likely, (2) possible, (3) unlikely, (4) unclear but possible, (5) unclear but unlikely.</p><p><strong>Results: </strong>We included nine studies in our review. (Val)acyclovir and favipiravir were considered possibly feasible for saliva-based TDM, whereas molnupiravir and oseltamivir were unclear but possible. Nirmatrelvir was deemed unclear but unlikely. For other included antivirals, no primary studies were available, however, physicochemical profiles suggest that salivary penetration may be feasible for some agents but limited for others.</p><p><strong>Conclusion: </strong>Studies documenting both saliva and plasma concentrations were scarce, and data was inconsistent. Findings from clinical studies sometimes contradicted predictions of penetration based on drug properties, suggesting that other factors, such as drug transporters, may significantly influence the salivary excretion of antivirals. Future robust, standardised investigations are required to confirm the clinical utility of saliva-based TDM. Feasibility is therefore currently inconclusive, but preliminary evidence is promising.</p>","PeriodicalId":10405,"journal":{"name":"Clinical Pharmacokinetics","volume":" ","pages":"1155-1172"},"PeriodicalIF":4.0000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13461875/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacokinetics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40262-026-01675-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: Immunosuppressed patients are susceptible to serious viral infections, often necessitating antiviral prophylaxis and/or treatment. Therapeutic drug monitoring (TDM) has been proposed to optimise drug exposure and clinical outcomes and is typically performed on full blood/plasma samples. Saliva offers a less invasive, patient-friendly approach, and this systematic review aims to assess the feasibility of saliva-based assays for antiviral TDM.

Methods: We conducted a search on MEDLINE, EMBASE and ClinicalTrials.gov databases, governmental regulatory websites and conference abstracts. Primary studies reporting both saliva and plasma concentrations of antivirals used forprophylaxis or treatment of opportunistic viral infections were included. Physicochemical properties of eachantiviral were compiled from PubChem and DrugBank to predict salivary excretion. Feasibility classifications were defined as follows: (1) likely, (2) possible, (3) unlikely, (4) unclear but possible, (5) unclear but unlikely.

Results: We included nine studies in our review. (Val)acyclovir and favipiravir were considered possibly feasible for saliva-based TDM, whereas molnupiravir and oseltamivir were unclear but possible. Nirmatrelvir was deemed unclear but unlikely. For other included antivirals, no primary studies were available, however, physicochemical profiles suggest that salivary penetration may be feasible for some agents but limited for others.

Conclusion: Studies documenting both saliva and plasma concentrations were scarce, and data was inconsistent. Findings from clinical studies sometimes contradicted predictions of penetration based on drug properties, suggesting that other factors, such as drug transporters, may significantly influence the salivary excretion of antivirals. Future robust, standardised investigations are required to confirm the clinical utility of saliva-based TDM. Feasibility is therefore currently inconclusive, but preliminary evidence is promising.

唾液用于抗病毒治疗药物监测的可行性如何?系统回顾与分析。
背景和目的:免疫抑制患者容易发生严重的病毒感染,通常需要抗病毒预防和/或治疗。治疗性药物监测(TDM)已被提出用于优化药物暴露和临床结果,通常在全血/血浆样本上进行。唾液提供了一种侵入性较小、对患者友好的方法,本系统综述旨在评估基于唾液的抗病毒TDM检测的可行性。方法:检索MEDLINE、EMBASE和ClinicalTrials.gov数据库、政府监管网站和会议摘要。初步研究报告了用于预防或治疗机会性病毒感染的唾液和血浆抗病毒药物浓度。从PubChem和DrugBank中编译了每种抗病毒药物的理化性质,以预测唾液排泄。可行性分类定义如下:(1)可能,(2)可能,(3)不太可能,(4)不清楚但可能,(5)不清楚但不太可能。结果:我们纳入了9项研究。(Val)阿昔洛韦和法匹拉韦被认为可能适用于基于唾液的TDM,而莫努匹拉韦和奥司他韦尚不清楚,但可能。Nirmatrelvir被认为不明确,但不太可能。对于其他包括的抗病毒药物,没有初步的研究,然而,物理化学特征表明,一些药物的唾液渗透可能是可行的,但对其他药物则有限。结论:记录唾液和血浆浓度的研究很少,数据也不一致。临床研究的结果有时与基于药物性质的渗透预测相矛盾,表明其他因素,如药物转运体,可能显著影响抗病毒药物的唾液排泄。未来需要强有力的、标准化的研究来证实基于唾液的TDM的临床应用。因此,可行性目前尚无定论,但初步证据是有希望的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.80
自引率
4.40%
发文量
86
审稿时长
6-12 weeks
期刊介绍: Clinical Pharmacokinetics promotes the continuing development of clinical pharmacokinetics and pharmacodynamics for the improvement of drug therapy, and for furthering postgraduate education in clinical pharmacology and therapeutics. Pharmacokinetics, the study of drug disposition in the body, is an integral part of drug development and rational use. Knowledge and application of pharmacokinetic principles leads to accelerated drug development, cost effective drug use and a reduced frequency of adverse effects and drug interactions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书